Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Novartis is also establishing a network of certified treatment centres throughout the country which will be fully trained on the use of Kymriah and appropriate patient care. Gilead in the picture ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Who Are the Key Players in the Kymriah Market? The Kymriah market is dominated by Novartis AG, a key player in CAR-T cell therapy innovation. Advancements in Kymriah and other CAR-T therapies have ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

A higher percentage of patients received axicabtagene ciloleucel (Yescarta, Kite Pharma; 62%) than tisagenlecleucel (Kymriah, Novartis; 38%). Median follow-up was 2.9 years. Forty-one patients (45 ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Legend Biotech), tisagenlecleucel (Kymriah, Novartis), brexucabtagene autoleucel (Tecartus, Kite Pharma/Gilead Sciences) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences).

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.